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1 Abstract 
1.1 Background 
Transverse myelitis (TM) is an immune-mediated disorder of the spinal cord affecting adults 
and children causing motor, sensory and autonomic dysfunction. A prolonged recovery 
phase which may continue for up to many years. Neuromyelitis-optica (NMO) is an 
uncommon relapsing inflammatory central nervous system (CNS) condition where TM can 
be the first presenting symptom. As TM and NMO affects many patients at the prime of 
their working life, the disorder can impose a significant demand on health resources. There 
are currently no robust controlled trials in children or adults to inform the optimal 
treatment of TM. However, treatment with intravenous immunoglobulin (IVIG) is being 
effectively used in the management of a range of neurological conditions. Although other 
interventions such as plasma exchange (PLEX) in addition to intravenous 
methylprednisolone therapy can be beneficial in TM, PLEX is costly and technically 
challenging to deliver in the acute setting. IVIG is more readily accessible and less costly. 
1.2 Objective(s) 
To evaluate if additional and early treatment with IVIG is of extra benefit in TM compared to 
standard therapy of intravenous steroids. 
1.3 Design 
A multicentre, single-blind, parallel-group randomised controlled trial of IVIG versus 
standard therapy for treatment of TM in adults and children. 
1.4 Participants 
Patients aged 1 or over who have been diagnosed with either acute first onset transverse 
myelitis or first presentation of NMO. A target recruitment of 170 (85 per arm) participants. 
1.5 Interventions 
Participants were randomised 1:1 to treatment with IV methylprednisolone only or IV 
methylprednisolone plus 2g/kg IVIG in divided doses within 5 days of first commencement 
of steroid therapy. 
5 
1.6 Main outcome measures 
Primary outcome measure: a two-point improvement in American Spinal Injury Association 
(ASIA) Impairment Scale 6-months post randomisation. Secondary and tertiary outcome 
measures: change in ASIA motor and sensory scores, Expanded Disability Status Scale 
(EDSS), health outcome, quality of life assessment, Client Services Receipt Inventory and 
pain, bladder and bowel data sets.  
1.7 Results 
26 participants were screened and two randomised into the study. With the limited sample 
size, treatment effect could not be determined. However, we identified barriers to accrual 
that included; strict inclusion criteria, short enrolment window, challenges associated with 
the use of ASIA impairment scale as an outcome measure and estimation of the incidence of 
TM. 
1.8 Limitations 
The study did not reach the end-point. 
1.9 Conclusions 
The effect of IVIG in TM/NMO could not be determined by this study. Investigators should 
be aware of the potential challenges associated with carrying out rare disease trial that 
recruits within a small time window. 
1.10 Future work 
The study question is one that still necessitates investigation. Preliminary work that would 
ameliorate the effect of the barriers encountered by this study is vital.  
1.11 Study registration 
EudraCT (REF: 2014-002335-34), Clinicaltrials.gov (REF: NCT02398994) and ISRCTN (REF: 
12127581). 
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1.12 Funding details 
National Institute for Health Research, Health Technology Assessment (project number 
11/129/148); Biotest AG, Germany (supply if IVIG); and The Transverse Myelitis Society 
(excess research cost to facilitate study initiation). 
Word count: 496 
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6 Scientific Summary 
6.1 Background 
Transverse myelitis (TM) is a rare inflammatory disorder of the spinal cord affecting 
approximately 350 children and adults annually in the UK. TM attacks usually develop over 
24 hours and in some cases can progress rapidly to a potentially devastating and sometimes 
life threatening condition. The severity of symptoms depends on the spinal cord level 
affected, where patients with high cervical lesions often require intensive care support to 
maintain respiratory function. Patients can recover fully from TM but a large number are left 
with significant disability. Among patients that recover, recovery occurs within weeks of 
onset of symptoms and is most rapid during the first 3–6 months, although further 
improvement may be seen up to 2-4 years. 
A proportion of patients initially diagnosed with TM will subsequently relapse, often with 
involvement of other parts of the central nervous system, and may often be diagnosed with 
either multiple sclerosis (MS) or neuromyelitis optica (NMO).  NMO is a relapsing subset of 
TM, usually caused by antibodies to aquaporin-4. Clinically, patients have recurrent episodes 
of predominantly myelitis and optic neuritis. Initial presentation may be with myelitis alone, 
making it clinically and radiologically indistinguishable from TM, and patients are thus 
subjected to the same acute therapeutic strategies. 
There are no robust controlled trials in children or adults to inform on the optimal 
treatment of TM. Standard treatment with intravenous methylprednisolone (IVMP) is based 
on class IV evidence that it shortens relapse duration and speeds recovery in exacerbations 
of adult multiple sclerosis. Given the disease severity and poor outcomes, plasma exchange 
(PLEX) has been used in addition to standard therapy with some effect. However, PLEX is not 
universally available in the NHS, particularly at short notice and on weekends, and can be 
technically difficult and costly to administer. Randomised controlled trials have 
demonstrated IVIG efficacy in a number of neurological conditions. In steroid-unresponsive 
CNS demyelination, IVIG is often used, although supporting data are limited to small case 
series and single case reports. IVIG appears to inhibit complement binding, neutralise 
pathogenic cytokines, down regulate antibody production, enhance remyelination and 
modulate phagocytosis and T-cell function. The majority of these factors are common across 
16 
inflammatory disorders of the CNS including TM, providing a strong rationale for its use. The 
availability, ease of administration, familiarity and safety also make IVIG an attractive option 
in the acute setting. 
6.2 Objective 
The primary aim of this study was to evaluate if additional, and early, treatment with IVIG is 
of extra benefit in TM when compared to the current standard therapy of IVMP. 
The secondary objectives of the study were to provide benefits whereby: - 
1. The clinical and para-clinical data collected from patients will provide a robust 
resource and platform for other clinical studies, including identification of early 
predictors of poor outcome. 
2. Bio banked samples from patients recruited to the study will be collected and used 
for carefully designed biological studies by a consortium of established basic science 
researchers in the field 
6.3 Method 
STRIVE study was a multicentre, single-blind, parallel-group randomised controlled trial with 
follow-up visits 3, 6 and 12-months following randomisation.  
Patients were considered for recruitment if aged 1 or over diagnosed with either acute first 
onset transverse myelitis or neuromyelitis optica; with an ASIA impairment score of 
between American Spinal Injury Association (ASIA) Impairment Scale A through to C; and 
within 5 days after commencing steroid treatment.  
Participants were randomised 1:1 to treatment with IV methylprednisolone alone (control 
arm) or IV methylprednisolone plus 2kg/kg IVIG in divided doses (treatment arm). Sample 
size calculation yielded a target recruitment of 170 participants, 85 participants per arm. 
Primary outcome was assessed 6-month post randomisation with a good outcome defined 
by a two-point change in ASIA impairment scale.  
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Additional outcomes were measured by: -Secondary endpoint measure 
1. Change in ASIA motor scale (0-100) and ASIA sensory scale (0-112) at 3, 6, and 12- 
months post randomisation 
2. Change in Kurtzke expanded disability status scale (EDSS) measured by Neurostatus 
scoring at 3, 6, and 12 months 
3. EQ-5D-Y for patients aged 8-12 years (at presentation) at 3,6 and 12 months 
4. EQ-5D-ϱL foƌ patieŶts aged ш ϭϯ Ǉeaƌs ;at pƌeseŶtatioŶͿ at ϯ, ϲ aŶd ϭϮ ŵoŶths
5. IŶdiǀiduals ш ϭϯ Ǉeaƌs at pƌeseŶtatioŶ: IŶteƌŶatioŶal “CI QualitǇ of Life BasiĐ Data “et 
at 3, 6 and 12 months 
6. Client Service Receipt Inventory (CSRI) at 3, 6 and 12 months 
Tertiary endpoint measure 
1. IŶteƌŶatioŶal “CI Bladdeƌ/Boǁel Data “et foƌ patieŶts aged шϭϯ Ǉeaƌs at pƌeseŶtatioŶ 
to be completed at 6 and 12-months post randomisation 
2. Children 2-4 years of age at pƌeseŶtatioŶ: PaediatƌiĐ QualitǇ of Life IŶǀeŶtoƌǇ™ 
(PedsQL Parent Report for Toddlers) at 6 and 12 months 
3. Children 5-ϳ Ǉeaƌs of age at pƌeseŶtatioŶ: PaediatƌiĐ QualitǇ of Life IŶǀeŶtoƌǇ™ 
(PedsQL Parent Report for Young Children) at 6 and 12 months 
4. IŶdiǀiduals ш ϭϯ Ǉeaƌs of age at pƌeseŶtatioŶ: IŶteƌŶatioŶal “CI PaiŶ BasiĐ Data “et at 
6 and 12 months 
6.4 Results 
Of the 28 patients screened for eligibility, two participants were randomised into the study 
between 04/03/2015 and 08/02/2016, precluding any statistical analysis of the data and 
consequently any differences in treatment outcomes between the two study arms could not 
be determined.  However, we identified multiple barriers to accrual into the study. These 
included; strict inclusion criteria, short enrolment window, challenges associated with the 
use of the ASIA impairment scale as the primary outcome measure, an inaccurate 
estimation of the incidence of TM severity within the target population and variability of 
research funding of individual sites. 
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6.5 Conclusions 
The clinical and health economic impact of the use of IVIG in addition to the standard 
therapy with IVMP in the treatment of adults and children with TM/NMO could not be 
determined by the study. As the study question is crucial to inform the acute treatment of 
TM/NMO patients, and thus one that necessitates further investigation, we recommend 
additional research to establish the incidence and the spectrum of severity of the disorder 
within the intended study population, alongside evaluating the utility of alternative primary 
outcome measures such as the ASIA motor score and other patient derived outcome 
measures. The success of future intervention trials in TM would be also be contingent on 
being able to overcome recruitment barriers identified in this study; which may have 
broader implications for investigators embarking on similar studies in other rare disorders.  
6.6 Trial registration 
This study is registered with EudraCT (REF: 2014-002335-34), Clinicaltrials.gov (REF: 
NCT02398994) and ISRCTN (REF: 12127581). 
Word count: 1079 
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7 Plain English Summary 
Transverse myelitis (TM) is a rare immune disorder that affects the spinal cord. Patients that 
develop TM can quickly lose the feeling and ability to move lower parts body (paraplegia). 
Additionally, the upper body can also be affected (tetraplegia). TM can affect anybody at 
aŶǇ age aŶd this disoƌdeƌ ĐaŶ haǀe a sigŶifiĐaŶt iŵpaĐt ďoth oŶ the ƋualitǇ of peoples͛ life 
and demand on health resources. 
Although immune treatments such as steroids, IVIG and plasma exchange are being used to 
treat TM, until now, no high quality trial has been conducted to measure how effective 
these treatments are when utilised individually or used in combination. Therefore, this 
randomised controlled study was designed to see if newly diagnosed TM patients would 
benefit from early treatment with IVIG if added to steroid therapy which we expect all 
patients to receive.  We measured the effect of treatment using the ASIA impairment scale, 
an outcome measure validated in spinal injury research; and using evaluators who were not 
aware of treatment of patients (single blind).  
After a year, despite 15 centres recruiting across the UK, only two patients were 
randomised. Key reasons for this include the strict inclusion criteria, short enrolment 
window, challenges associated with the use of the ASIA impairment scale as the primary 
outcome measure, an inaccurate estimation of the incidence of TM severity within the 
target population and inadequate funding provision for some sites. As 170 cases were 
required to determine a statistically significant effect of treatment, this study was closed 
early as this endpoint would not have been realistically achieved. However, we are now 
aware of important factors that need to be addressed when undertaking a trial in TM or 
allied rare condition.  
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8 Introduction  
8.1 Background 
Transverse myelitis (TM) is an immune-mediated disorder of the spinal cord affecting 
children and adults and is usually characterised by a rapid onset of paraplegia or tetraplegia, 
loss of sensation and sphincter disturbance.
1
 Histologically, TM is characterised by spinal 
cord immune cellular infiltration, and pathogenesis is mediated by a variety of 
immunological mechanisms.
1
Attacks usually develop over 24 hours, and in some cases can 
progress rapidly to a potentially devastating and life threatening condition. The severity of 
symptoms depends on the spinal cord level affected, where patients with high cervical 
lesions often require intensive care support to maintain respiratory function. Patients can 
recover fully from TM, but a large number are left with significant disabilities. Recovery 
occurs within weeks of onset of symptoms and is most rapid during the first 3–6 months, 
although further improvement may be seen up to 2-4 years.
2
Diagnostic criteria for TM were established by the TM Consortium Working Group in 2002.
3
A proportion of patients initially diagnosed with TM will subsequently relapse, often with 
involvement of other parts of the central nervous system (CNS), and may then be diagnosed 
with either multiple sclerosis (MS) or neuromyelitis optica (NMO). NMO is a relapsing subset 
of TM, caused by antibodies to aquaporin-4.
4
Clinically, patients have predominantly 
recurrent episodes of myelitis and optic neuritis. Neurodisability accrues with progressive 
relapses.  Initial presentation may be with myelitis alone, making it clinically and 
radiologically indistinguishable from TM, and patients are thus subjected to the same acute 
therapeutic strategies 
The precise numbers that make full recoveries from TM remains unclear. Studies prior to 
the TM Consortium Working Group criteria may have included patients with a wider range 
of myelopathies such as spinal cord infarction,
5
 or may reflect the greater severity of cases 
seeŶ at a teƌtiaƌǇ ƌefeƌƌal ĐeŶtƌe suĐh as the JohŶ͛s HopkiŶs TM CeŶtƌe,6 where up to 20% 
are reported to make a good recovery. Currently, the only report to reliably inform on the 
outcome of adult onset TM is a retrospective French multicentre study applying TM 
Consortium Working Group criteria, where 36% of patients with TM had a poor prognosis as 
defined by death or non-ambulating.
7
 In children, approximately half make a good 
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recovery.
8
 Hence, the majority of adults and children presenting with TM either have a fair 
outcome (functional and ambulatory, but with varying degrees of spasticity, urgency and/or 
constipation, and some sensory signs) or worse (remaining completely or largely unable to 
walk, having at best partial sphincter control, and being left with severe sensory deficits.
2
These results represent a huge burden on patients and their carer. With conservative 
estimates of incidence of TM in UK being 350/year (based on incidence of 3-7 per 
million),
9,10
 this clearly imposes a significant cumulative demand on the health resources in 
the UK. Moreover, many patients are affected at peak ages that reflect their prime working 
life, thus resulting in loss of productivity and imposing a further financial impact on the 
country. 
Importantly, strategies to reduce the disability in patients are urgently required, yet there 
are no robust controlled trials, in children or adults, to inform on its optimal treatment. The 
current clinical consensus is derived from data that are mainly extrapolated from Class IV 
evidence from case series or clinical trials for the treatment of exacerbations of adult 
multiple sclerosis.
9-12
 In adults, this suggests that treatment of relapses with intravenous (IV) 
methylprednisolone shortens relapse duration and speeds recovery. It is from this that the 
current standard therapy has been based whereby, in both children and adults, treatment 
with high dose IV steroids is prescribed for 3-7 days to reduce inflammation, hasten 
recovery and restore neurological function.
13
Although IV steroids are now the most common treatment for TM, there are other 
interventions which have proved effective in aiding recovery, but which are not routinely 
applied.  In a retrospective analysis of 122 adults with TM, acute therapies given at one 
centre between 2001 and 2005 were evaluated, with the finding that some patients 
benefited from the addition of plasma exchange (PLEX) to IV methylprednisolone.
11
The 
efficacy of PLEX was also demonstrated in a small randomised controlled trial in adults with 
acute central nervous system (CNS) demyelination (including 4 patients with TM) where 
steroids had failed to induce a remission of symptoms.
14
 However, administering PLEX is 
technically difficult and costly, making it challenging to deliver within the NHS, resulting in it 
not being universally available.   
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Treatment with intravenous Immunoglobulin (IVIG) is also used increasingly in the 
management of a range of neurological conditions, and its efficacy has been established 
clearly in randomised controlled trials for a handful of these conditions.
15
 In adults and 
children with CNS demyelination who do not respond to steroids, IVIG is often used, 
although supporting data is limited to small case series and single case reports.
16,17
The most 
relevant actions of IVIG in the therapy of neurological diseases include: (a) inhibition of 
complement binding, (b) neutralization of pathogenic cytokines, (c) down-regulation of 
antibody production, and (d) modulation of Fc-receptor mediated phagocytosis. Additional 
actions include modulation of T-cell function and enhancement of re-myelination.
18
 The 
majority of these factors are common across inflammatory disorders of the CNS including 
transverse myelopathy,
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 providing a strong rationale for its use in the management of TM. 
In addition, IVIG is cost effective when compared to PLEX and more readily accessible.  
Here, we aimed to conduct a multi-centre, single blind, parallel group randomised-
controlled trial to generate evidence to inform clinical and health economic decisions of IVIG 
use in adults and children with TM. 
8.2 Risks and Benefits 
Risks: This study includes adults and children. As treatments in both arms of the trial are 
already used in current clinical practice, those participating will face almost no additional 
risk beyond what they would experience in treatment outside the trial.    
Benefits: Interventions that can reduce the disability in patients are urgently required. The 
current management recommendation is largely based on expert opinion,
13
 as there remain 
no robust controlled trials for the treatment of TM, in children or adults, to inform on the 
optimal treatment of TM. This trial seeks to evaluate if IVIG would be beneficial in the 
management of TM. 
8.3 Study aim 
This multicentre, single blind, parallel group RCT was aimed at generating evidence to 
inform clinical and health economic decisions regarding IVIG use in adults and children with 
TM.  
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The primary objective of this single blind, parallel group randomised controlled trial was to 
evaluate if additional, and early, treatment with IVIG is of extra benefit in TM when 
compared to the current standard therapy of intravenous steroids.  
In addition, our secondary objectives were to provide benefits whereby: - 
1. The clinical and para-clinical data collected from patients will provide a robust 
resource and platform for other clinical studies, including identification of early 
predictors of poor outcome.  
2. Bio bank samples from patients recruited to the study will be collected and used for 
carefully designed biological studies by a consortium of established basic science 
researchers in the field. 
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9 Methods and material 
9.1 Trial Design 
This was a UK multi-centre, single blind, parallel group randomised controlled trial.  
Patients randomised to the control arm of this study were prescribed IV 
methylprednisolone in line with local clinical practice. Recommended dosages are as listed 
below: - 
1. Paediatric patients will receive 30 mg/kg or 500 mg/m
2
 capped to a maximum dose 
of 1 g/day  
for 5 days.  
2. Adult patients will be given 1 gram/day for 5 days. 
Patients in the intervention arm received the above standard therapy plus additional IVIG: 
1. In adults, 2 g/kg will be administered in 5 divided doses 
2. In children who are > 41.2kg, 2g/kg will be administered as above in adults; in 
children who are  
ч ϰϭ.Ϯkg, Ϯg/kg ǁill ďe adŵiŶisteƌed iŶ Ϯ diǀided doses
Though IVIG dosing does not need to be administered over consecutive days, it must be 
administered according to the dosing schedule (Appendix 1). 
Patients may be recruited and randomised up to 5 days from the date of first commencing 
steroid therapy or up to 21 days from the onset of symptoms (if definitely known).  
In patients who do not respond to standard IV methylprednisolone treatment or adjunctive 
treatment with IVIG, rescue therapy, such as PLEX, would have been instituted. 
If PLEX is administered, such a therapy will attenuate treatment effect of IVIG and may 
indeed have a treatment effect of its own, guidance parameters were set out to define and 
standardise PLEX regime. Briefly: 
1. Treatment failure would be considered if no improvement is seen or deterioration 
occured after 14 days from presentation or 5 days after completion of either 
treatment arm. 
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2. A complete PLEX treatment would comprise of at least 5 cycles, of which in each 
cycle at least 75% of plasma volume is exchanged, with a 24-48-hour interval 
between each cycle.  
3. An extra course of intravenous methylprednisolone may be given by physicians, 
often during the lag phase, from decision to proceed with rescue therapy to its 
initiation (usually 5-7days). 
9.2 Endpoint measure 
9.2.1 Primary endpoint measure 
An improvement of two-points or greater on the ASIA Impairment scale (classified A-E) at 6-
months post-randomisation, compared to the value measured at baseline just prior to 
randomisation. 
9.2.2 Secondary endpoint measures 
1. Change in ASIA motor scale (0-100) and ASIA sensory scale (0-112) at 3, 6, and 12 
months post randomisation  
2. Change in Kurtzke expanded disability status scale (EDSS) measured by Neurostatus 
scoring at 3, 6, and 12 months  
3. EQ-5D-Y for patients aged 8-12 years (at presentation) at 3,6 and 12 months 
4. EQ-5D-5L for patients aged ш ϭϯ Ǉeaƌs ;at presentation) at 3, 6 and 12 months 
5. IŶdiǀiduals ш ϭϯ Ǉeaƌs at pƌeseŶtatioŶ: IŶteƌŶatioŶal “CI QualitǇ of Life BasiĐ Data “et 
at 3, 6 and 12 months 
6. Client Service Receipt Inventory (CSRI) at 3, 6 and 12 months 
9.2.3 Tertiary endpoint measures 
1. International SCI Bladder/Bowel Data Set foƌ patieŶts aged шϭϯ Ǉeaƌs at pƌeseŶtatioŶ 
to be completed at 6 and 12-months post randomisation 
2. Children 2-4 years of age at presentation: Paediatric Quality of Life Inventory™
(PedsQL Parent Report for Toddlers) at 6 and 12 months 
3. Children 5-7 years of age at presentation: Paediatric Quality of Life Inventory™
(PedsQL Parent Report for Young Children) at 6 and 12 months 
26 
4. IŶdiǀiduals ш ϭ3 years of age at presentation: International SCI Pain Basic Data Set at 
6 and 12 months 
The overall flow of study participants from admission through to randomisation and final 
visit is summarised in Figure 1.
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Figure 1. STRIVE participant flow chart
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9.3 Study Subjects 
Participants were individuals who met the eligibility criteria and diagnostic algorithm 
(Appendix 2) and present to the catchment area of participating tertiary neurology centres 
(though neurologists may also recruit patients at district general hospitals or from rapid GP 
referrals). Eligibility for the study will be determined by the following criteria: - 
9.3.1 Inclusion Criteria  
Patients were eligible for inclusion in the trial if on presentation they: 
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ii. Spinal cord MRI with contiguous T2-weighted signal abnormality 
extending over three or more vertebral segments, indicating a relatively 
large lesion in the spinal cord 
iii. Aquaporin 4 seropositive status) 
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9.3.3 Sample size 
In recognition of TM as a rare condition, the power analysis took into account the inclusion 
of a futility analysis to be undertaken after recruitment of one third of the target sample.  
We assumed that the proportion of participants showing a 2-point improvement (or 
greater) on the ASIA Impairment scale will be approximately 0.5 (50%) in the control arm 
and a minimum of 0.75 (75%) in the intervention arm. The sample size calculation was 
based on the conservative assumption of no correlation between repeated measures.   
Randomised 1:1, the primary ITT analyses will compare 76 treatment and 76 control 
patients, on the ASIA classification scale at 6-months post randomisation. Based on 
comparing the difference in the number of successes among treatment and controls the SAS 
sample size – chi procedure examines all 772 possible trial outcomes under the null and 
alternative hypotheses. The possible outcomes are then arranged in descending order and 
cumulative probabilities for every possible value from 76 to -76 are computed.  Using a 
critical value that maintains the tail probability at .02355 under the null the probability 
under the alternative is 0.9034. The study thus had 90% power for a two-tailed test with 
alpha=0.05. 
The sample size was inflated for attrition, based on our experience and the design in place 
to minimise any loss to follow up, we estimated 10% attrition. This would require recruiting 
a sample size of (n=152/0.90) = 170 (85 participants per arm).   
The ASIA total motor score (0-100) was a secondary outcome. There is little evidence in 
acute transverse myelitis to summarise this in terms of variance, mean and correlation.  
Stata sampsi indicates that using ANCOVA, with a baseline to endpoint correlation of 0.6, 
there will be 87% power to detect a difference between the control and treatment arms of a 
medium to large effect size of 0.4.  Such a difference will be of clinical significance. 
9.3.4 Randomisation 
Treatment allocation will be stratified at randomisation, by service type (adult or child) using 
stratified block randomisation; the block will randomly vary in size. Treatment allocation will 
be at a ratio of 1:1. 
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9.3.5 Withdrawal  
The patient, or their parent/guardian, had the right to withdraw from the study at any time 
for any reason. The investigator also had the right to withdraw patients from the study drug 
in the event of inter-current illness, AEs, SAEs, and SUSARs, subsequent evidence of a 
different aetiology, protocol violations, cure, administrative or other reasons.  Participants 
who either wished to or must discontinue study medication would be returned to standard 
care through their supervising physician, but will continue to provide study specific data at 
follow up visits at 3, 6 and 12 months. It was understood that an excessive rate of 
withdrawals can jeopardise randomisation outcomes and render the study results 
uninterpretable; therefore, unnecessary withdrawal of patients was avoided.  Should a 
patient had decided to withdraw from the study, all efforts would have been made to report 
the reason for withdrawal as thoroughly as possible. 
9.4 Study data 
The study data was managed as previously described in the published STRIVE protocol.
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9.4.1 Data management
Data was managed using the InferMed MACRO database system. An electronic case report 
form (eCRF) was created using the InferMed Macro system. This system is regulatory 
compliant (GCP, 21CRF11, EC Clinical Trial Directive). The eCRF was created in collaboration 
ǁith the tƌial statistiĐiaŶs aŶd the Đhief iŶǀestigatoƌ ;CIͿ aŶd ŵaiŶtaiŶed ďǇ the KiŶg͛s CliŶiĐal 
Trials Unit. It was hosted on a secure dedicated server within KCL and source data was 
entered by authorised staff onto the eCRF with a full audit trail. 
9.4.2 Database passwords
Database access was strictly restricted through passwords to the authorised research team. 
The CI or site delegate requested access from the KCTU. If a new staff member joined the 
study, a personalised username and password was requested via the CI or delegate.  
9.4.3 Identifiable data 
All participant contact information data was stored within the recruiting NHS site, which will 
have restricted access from password protected computers. Accrual data uploaded to the 
UKCRN portfolio database was anonymised and collated by the CI or Trial manager to the 
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CLRN. No identifiable data was entered on the eCRF or transferred to the KCTU. Participants 
were identified on the study database using a unique code and initials. Each investigator 
maintained accurate patient records detailing observations on each patient enrolled. 
9.5 Investigational medicinal product 
Investigational medicinal product (IMP) was provided as human normal immunoglobulin 
(Intratect®) 100g/l solution for infusion in single 5g (50ml) or 10g (100ml) glass vial. Biotest 
Pharma GmbH, marketing authorisation holder of Intratect®, provided the commercially 
available Intratect® for use. 
Annex 13 clinical trial labelling exemption was in place and approved by the Medicines and 
Healthcare Products Regulatory Agency (MHRA) for this trial. A standard pharmacy 
dispensing label was applied to the IMP at the point of dispensing by pharmacy at each 
investigator site.  
IMP was stored in a secure area with limited access. Site pharmacies were responsible for 
the safe and appropƌiate stoƌage of IMP at theiƌ site iŶ aĐĐoƌdaŶĐe ǁith ŵaŶufaĐtuƌeƌs͛ 
instructions (as described below).  
IŶtƌateĐt® stoƌage ĐoŶditioŶs iŶ aĐĐoƌdaŶĐe ǁith ŵaŶufaĐtuƌeƌs͛ iŶstƌuĐtioŶs: 
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Note that IV methylprednisolone (as sodium succinate) was classed as non-investigational 
medicinal product in this trial and was dispensed by hospital pharmacies in accordance with 
their standard clinical practice.   
9.5.2 Risks  
The current risks associated with the Intratect® immunoglobulin are detailed in the 
Intratect® Summary of Products Characteristics (SmPC) which can be found at 
https://www.medicines.org.uk. A summary of these risks are provided in Appendix 3.
9.5.3 Compliance 
Treatment with the IMP was administered under the supervision of the investigator and in a 
controlled clinical environment. Therefore, full patient compliance with treatment was 
anticipated. 
9.5.4 Concomitant Medication 
Only relevant immuno-modulatory medications were recorded throughout the study. 
In patients who do not respond to control treatment or adjunctive treatment with IVIG, 
rescue therapy will be instituted in accordance with local guidelines. In most cases the 
rescue therapy of choice will be PLEX therapy. This will also be recorded as a concomitant 
medication. 
9.5.5 Confidentiality 
The study staff ensured that the paƌtiĐipaŶts͛ aŶoŶǇŵitǇ was maintained, identifying 
patients by their PIN numbers and initials only. The study complied with the Data Protection 
Act, which requires data to be anonymised as soon as it is practical to do so. 
9.6 Trial sites and study duration 
The study was conducted across 15 clinical sites within the UK, with the addition of a single 
site that acted as a participant information centre (PIC). The first of the 15 sites was opened 
for recruitment on 04/03/2015, whilst the final site received its approval to commence 
recruiting on 08/02/2016. Recruitment was terminated early across all the 15 recruiting 
sites and the single participant identification centre on 11/03/2016.  
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9.7 Trial procedure 
For every time point in the study, a number of questionnaires/ exam forms and assessments 
was carried out, as summarised in Table 1. Some of the questionnaires were specific to 
particular age groups, with age on presentation being used. 
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Table 1. A summary of the STRIVE study visit schedule and associated assessments 
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Screening with diagnostic 
algorithm & core investigations 
including physical exam
x
Patient information and informed 
consent
x
Eligibility form x
Registration form x
Pre-diagnosis Tests – e.g. MRI & 
AQP4  
x
Randomisation x
Biobank samples x x
ASIA Impairment Score (A-E) x x x x P x
ASIA Motor and Sensory Score x x x x S x
Neurostatus scoring (Kurtzke 
functional systems and EDSS)
x x x S x
8-12 yrs  EQ-5D-Y Questionnaire x x S x
ш13 yrs EQ-5D-5L Questionnaire x x S x
CSRI Questionnaire† x S x
шϭϯ Ǉƌs “CI QoL BasiĐ dataset† x S x
шϭϯ Ǉƌs “CI Bladdeƌ Basic dataset T x
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шϭϯ Ǉƌs “CI Boǁel Basic dataset T x
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шϭϯ Ǉƌs “CI PaiŶ BasiĐ dataset† T x
5-7 yrs Peds QL Questionnaire† T x
2-4 yrs Peds QL Questionnaire† T x
Treatment form x
Concomitant medications x
Discharge form x
*Rescue therapy form
(if needed)
x
*Relapse form (at any time point 
if needed)
x x x x
Adverse events x
Study Status Form x x x
*Withdrawal form (at any time 
point)
x
P = primary outcome S = secondary outcome T = tertiary outcome 
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9.7.1 Blinding 
Due to the technical challenges of masking IVIG from saline, the need for rapid recruitment 
and the fact that follow-up will be many months after the event using objective well-defined 
clinical endpoints; treatment will not be blinded (no placebo). The trial manager, pharmacy, 
and those administering treatment are not blinded; whilst staff carrying out primary 
outcome assessments at follow-up and statistical analyses will be blinded to intervention. 
Screening, baseline and discharge assessments were carried out in the tertiary centres by a 
study physician/research nurse. Following discharge from treatment in hospital, all primary 
outcome assessments at follow up in clinic at the tertiary centre or appropriate neurology 
centre, were carried out by a study physician/research nurse/physiotherapist who has been 
blinded to treatment. For consistency, wherever possible, the same blinded assessor was 
required to out the assessments at each time point. Although not mandatory secondary and 
tertiary outcome assessments were to be performed by a blinded member of staff at follow-
up wherever possible. 
9.7.2 Laboratory Tests  
All consenting patients had samples taken for clinical investigations and biobanking, at 
baseline and at the 6 month follow up. In cases, where samples for clinical investigations 
were already taken prior to consent, any left-over material will be used for biobanking. No 
additional samples will be collected unless there is a clinical indication to do so. Samples for 
biobanking will consist of CSF via lumbar puncture, and blood taken by venepuncture for 
serum, plasma, DNA, Peripheral Blood Mononuclear cells (PBMC) and RNA (site dependent), 
and will be stored in one of the two biobanks (London or Cardiff). These samples did not 
form part of this trial, but were for further hypothesis driven biological research, directed by 
Neil Robertson and Gavin Giovannoni (adults) and Ming Lim (paediatrics).  
9.7.3 MRI Sequences 
As part of the routine diagnostic process for TM/NMO, brain and spinal cord sequences 
ǁeƌe aĐƋuiƌed ǁheƌe possiďle, the ƌesults, of ǁhiĐh ǁas used iŶ the studǇ͛s diagŶostiĐ 
algorithm at screening and if the patient entered the trial, was recorded as study data.  
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Local protocols were in place for the acquisition of MRI sequences, which would usually 
include gadolinium enhanced sequences in the event of a suspected TM/NMO. 
To facilitate systematic accrual of neuroimaging information it was recommended that 
reports included: 
1. Location of the lesion (which spinal cord level) 
2. Size of the lesion (in terms of how many vertebral segments) 
3. Whether gadolinium injection was used and if so, was enhancement seen 
During the trial period, the study team were able to request anonymized patients scans to 
be provided on a CD to resolve potential clinical and radiological uncertainties. 
9.8 Analysis  
A comprehensive statistical analysis plan was developed and descriptive analysis (e.g. 
summary statistics and plots) was to be performed to investigate the distribution of the 
primary outcome, ASIA Impairment Scale score, across participants.  
9.8.1 Statistical Analysis 
All analyses were to be pragmatic and follow the intention to treat (ITT) principle, that is, 
patients will be analysed in the groups to which they were randomised irrespective of 
treatment amount or treatment quality received, utilising all available follow-up data from 
all randomised patients. Sensitivity analyses will be used to assess the robustness of 
conclusions to missing outcome data and to departures from randomised treatment.  
An interim futility analysis was scheduled to be conducted after 52 patients had provided a 
response (26 on each treatment arm), the endpoint being a two-point change in the ASIA 
scale 6 months after randomisation; the results were to be assessed by the Data Monitoring 
Committee. 
The final analysis of effectiveness was scheduled to be conducted once the trial database 
had closed, if the study continued to full recruitment. The Data Monitoring Committee were 
to collate effectiveness and safety data during the trial to inform their recommendations to 
the Trial Steering Committee. Main effects was planned to be summarised by intervention 
arm and assessment time point with associated 95% Confidence Intervals. 
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9.8.2 Primary and secondary outcome analysis 
The main objective of the statistical analysis was to assess the effect of IVIG on the primary 
outcome, a two-point change from baseline on the ASIA classification (A-E) scale, at 6-
months post randomisation.  
The secondary clinical assessments (EDSS, continuous ASIA motor and sensory scales, SCI, 
Paediatric quality of life, EQ5D and CSRI), with repeated measurements was also going to be 
analysed within a linear mixed model framework, where generalisations of the linear mixed 
model will be utilised to allow for outcomes with non-normal data if necessary. Those 
measures with one follow up assessment were to be evaluated with a general linear model. 
The statistical modelling was designed to feature the outcome measure(s) as the dependent 
variable with corresponding baseline measure(s) (if applicable), stratification factors and 
treatment group featuring as covariates. 
As descriptive analyses, recruitment rate, consent rate, loss to follow-up, departures from 
randomised treatment and the prevalence of serious adverse events (specifying deaths and 
ITU admissions), were to be reported at 3, 6 and 12-months post-randomisation and 
summarized by treatment arm over the course of the study. Chi-sƋuaƌed ;Fisheƌ͛s eǆaĐt testͿ 
was to be used for categorical outcomes (e.g. serious adverse events and mortality). 
All analyses were scheduled to be repeated considering age status (adult or child) and 
putative biological markers as moderators by interaction with treatment group (control or 
intervention), allowing estimates of treatment effect in the sub populations to be 
summarized. 
Explanatory analyses to assess the efficacy of the treatment within NMO or idiopathic TM 
diagnosis by allowing for an interaction with treatment arm were to be carried out.  The ICC 
of the sites would have been explored by allowing for site as random effect in the statistical 
modelling.   
With regards to missing data in post treatment outcome variables that would have arisen as 
participants discontinue treatment or are lost to follow-up, regression analyses based on 
maximum likelihood and resulting inferences would be valid provided the missing data 
geŶeƌatiŶg ŵeĐhaŶisŵ is ŵissiŶg at ƌaŶdoŵ ;MA‘Ϳ, that is ͞ŵissiŶgŶess͟ is pƌediĐted oŶlǇ 
by variables that are included in the model, including earlier values of the outcome variable.  
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We aimed to empirically assess whether any baseline variables predict missingness and 
should this be the case we would condition on such variables by including them in the 
statistical model. Sensitivity analyses would have been used to assess the robustness of 
conclusions to missing outcome data and to departures from randomised treatment as 
previously described by White et al, 2011.
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9.8.3 Futility analysis 
As previously mentioned, an interim futility analysis was scheduled to be conducted after 52 
patients had provided a response, 26 on each treatment arm, with the endpoint being a 
two-point change in the ASIA scale at 6 months. The trial would have been terminated with 
the conclusion that the new treatment is no better than standard if, based on these 52 
patients, the test statistic is less than zero.  If sample sizes were equal, this would occur if 
the successes under new treatment were fewer than under standard. Otherwise, the trial 
would proceed to the full sample size of 170. The SAS program two stage - interim - chi 
evaluates the design deleting outcomes that would correspond to futility.  The tail 
probabilities under the null and alternative were 0.0228 and 0.8946. The inclusion of the 
futility analysis therefore represented a very small loss of power.   
The SAS program two stage - stage1 - chi evaluates the properties of the first stage of the 
design.  It showed that the probability of abandoning the study at the interim analysis is 
0.4449 under the null and 0.0201 under the alternative.  Thus, there was a good chance of 
stopping for futility when the treatments were equivalent and a very small chance when the 
desired treatment effect was present (see Appendix 4 for Futility Analysis Plan). 
9.8.4 Health economic analysis
The study team aimed to develop a health economic module structure and complete a write 
up of its economic analysis, within the 12 months following the end of patient data 
collection (i.e. 42 – 54 months from the start date). 
Drug pricing data and primary care, secondary care and social care costs will be calculated 
as previously described. Costs will be combined with the primary outcome measure in the 
form of a cost-effectiveness analysis. If IVIG results in higher costs and better outcome, then 
an incremental cost-effectiveness ratio will be generated to show the extra cost incurred to 
achieve an extra unit of improvement. Owing to the uncertainty around results, cost-
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effectiveness planes and cost-effectiveness acceptability curves will be used, with 
bootstrapping of skewed results. 
Long-term cost-effectiveness over 5-year and 10-year periods will be calculated using a 
Markov model. Response to treatment will be classified, and transition probabilities 
between groups will be derived from 6-month and 12-month follow-up data. Costs and 
QALYs for each category will be derived from the trial data. As limited data will be available 
on long-term costs, we will conduct both deterministic and probabilistic sensitivity analyses. 
All Đauses of ǁithdƌaǁal fƌoŵ ƌaŶdoŵised tƌeatŵeŶt ǁill ďe ƌepoƌted. χϮ ;Fisher's exact 
test) will be used for categorical outcomes (eg, serious adverse events and mortality). 
There will be missing data in post-treatment outcome variables as participants discontinue 
treatment or are lost to follow-up. Inferences will be valid provided the missing data 
generating mechanism is missing at random (MAR), and is not predicted by any variables in 
the model, that is, missingness is predicted only by variables that are included in the model. 
The use of IVIG, IVMP, additional treatments and rescue PLEX will be recorded throughout 
the follow-up period and costed using drug pricing data from the British National Formulary 
and the Department of Health. Use of primary care, secondary care and social care will be 
recorded at three-month, 6-month and 12-month follow-ups using the CSRI, and costs 
calculated to determine total cost for THE control and treatment arms. 
A cost-effectiveness analysis will be performed using the primary and secondary outcome 
measures of improvement in ASIA scores, and secondary outcome of QALYs with EQ-5D-Y, 
EQ-5D-5L and CSRI. If IVIG results in higher costs and better outcome, then an incremental 
cost-effectiveness ratio will be generated to show the extra cost incurred to achieve an 
extra unit of improvement. 
9.9 Ethics and approvals 
This study is registered with EudraCT (REF: 2014-002335-34), Clinicaltrials.gov (REF: 
NCT02398994) and ISRCTN (REF: 12127581). Research Ethics Committee approval was 
obtained (South Central—Berkshire B; REC 14/SC/1329); alongside MHRA notification.   
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10 Trial outcome and results  
Over the 53 weeks of recruitment, 26 potential participants were screened for eligibility 
across all 15 sites. Of these 26 participants, 24 were not randomised [ineligible (n=23, with 
48% of these (11 of 23) too mild for inclusion and the remaining 52% (12 of 23) ineligible as 
they do not meet other inclusion or meet the exclusion criteria); and delay in referral of 
patient to PI (n=1). Two participants recruited into the study (Figure 2). One participant 
each was randomised to each arm of the trial,  with each participant followed up for six 
months post randomisation prior to withdrawal from the study. This data is summarised in 
the CONSORT diagram (Figure 2). The number of participants randomised into the study 
was significantly below the target sample size, thus precluding any form of data analysis and 
detection of significant difference between the control and treatment arms of the study. 
10.1 Baseline and three-month data summary 
Descriptive summarisation of both participants͛ data was carried out following a lock of the 
study data, and the trial statistical team remained masked to treatment allocation up to this 
point. One was a white female child, aged between 10 and 15, a student with unknown BMI. 
This participant had an ASIA impairment score of C prior to randomisation, meaning that 
motor function is preserved below the neurological level and more than half the key 
muscles below this level have muscle grade less than 3. At 3-months post randomisation this 
participant had improved to ASIA impairment score of D meaning that at least half of the 
key muscle functions below the neurological level have a muscle grade of 3 or above. The 
other participant was a white adult male, aged between 60 and 65, in full-time employment 
with a BMI of 30. This participant had an ASIA impairment score of A prior to randomisation, 
meaning that no motor or sensory function is preserved in sacral segments S4 to S5. At 3 
months post randomisation, this participant had not improved. Neither participant suffered 
a relapse during the trial. The adult participant suffered from two adverse events during the 
trial, a chest infection and pressure sores, which were not related to the trial, the paediatric 
participant suffered no adverse events. Due to the very small sample size it is not possible to 
comment on whether there is any relationship between the trial arm and any change in 
ASIA impairment scores. 
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10.2 Withdrawal  
Both randomised patients remained on the trial until their second follow-up visit (6-months 
post randomisation), at which point they were withdrawn from the study by the study team.  
The rationale behind the termination and subsequent withdrawal were explained to both 
participants, both of whom have recourse to further information. 
10.3 Health economics analysis 
As the trial did not recruit to a sufficient number, analysis of the health economic impact 
was not possible. 
10.4 Investigator (opinion leader) feedback 
Following the termination of the study, the study team developed a survey that sought to 
both gain feedback on the study, as well as develop a better understanding of the reason, in 
the opinion of the investigator, the study did not recruit to target. The survey questions 
were sent to 13 of the 15 recruiting sites, as the remaining two sites were those of the chief 
investigator and the co-investigator/ Project co-ordinator, both of whom were involved in 
the design of the survey. Of the 13 investigators contacted, 11 responses were received. A 
summary of these responses are detailed in Table 2.
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Figure 2. The Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
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Table 2.  Summary of the post-study survey of sites that that took part in the STRIVE study 
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11 Discussion: Lessons learnt from early closure of the trial  
The STRIVE study aimed to elucidate the added benefit in clinical efficacy and health 
economics associated with additional and early treatment of TM with IVIG when compared 
to the current standard therapy of IV steroids. Owing to the fact that the study under 
recruited, the study is unable to detect these difference. Nevertheless, the barriers 
encountered during the course of the trial are herein discussed. Other researchers planning 
a similar study would benefit from being aware of these barriers and its potential impact. 
11.1 Overview of the trial evolution 
The first STRIVE recruiting site received the green light to start recruiting on 04/03/2015, 
while the final site to receive its approval did so on 08/02/2016. At the point of the study 
suspension (11/03/2016), 15 sites were open to recruitment, with two sites each recruiting 
one subject. The Trial Steering Committee (TSC) met on 11/03/2106, where strategies to 
further improve recruitment into the study was extensively discussed. Following this 
meeting, the TSC and Trial Management Group (TMG) jointly decided that further 
recruitment into the study should be suspended with immediate effect. The TSC and TMG 
came to this decision because the study, on its current trajectory, was unlikely to recruit to 
sufficient numbers as to allow scientifically valid deductions to be made. The study 
coordinating team consulted the National Institute for Health Research (NIHR) monitoring 
team and following further discussion with the respective programme directors, early 
termination of the study was agreed upon.  
11.2 The need for better understanding of TM epidemiology  
A lower than expected frequency of patient encounters is believed to be the main factor 
that led to the low levels of recruitment observed in this study. The challenges associated 
with recruitment into rare disease trials are not restricted to this study alone.  A large scale 
comparison of interventional trials (24,088 trials) of which 2,759 (11.5%) were classified as 
rare disease trials and 21,329 (88.5%) non-rare conditions found that rare disease trials are 
more likely to be terminated early (13.7%) compared to non-rare disease trials (6.3%).
23
  The 
same study found that on average, the proportion of the actual number of patients 
recruited into a study compared to initial estimate is less for rare disease trials (70.1%) 
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compared to trials of non-rare conditions (81.6%). It is perhaps intuitively understandably 
that due to the uncommon nature of the disorder under study, one of the most frequent 
problem faced during the conduct of a rare disease trial is recruitment of the requisite 
number of study subjects.
23,24
The trial team were aware of the challenges associated with recruitment into rare disease 
trials and prior feasibility assessment suggested a higher frequency of patient encounter 
than was eventually observed. With the yearly incidence of TM being approximately 350 
(105 proportionately across the 15 open sites; based on study team projection that 24 sites 
would capture 50% of cases on TM in UK), the relatively low rate of patient encounter 
reported by all sites was unexpected. Furthermore, based on our estimated 35% 
recruitment rate, approximately 36 subjects could theoretically have been recruited by the 
open sites per year, against the two actually recruited. Interestingly, although numerous 
evidence (screening log, informal discussions with recruiting site personnel and the 
investigator survey response) point towards a low rate of patient encounter, anonymised 
data provided by the transverse myelitis patient group, Transverse Myelitis society (TMS), 
showed that approximately 61 registered members of their society (of whom 57 had a 
confirmed TM diagnosis) reported to having been diagnosed with TM in 2015 (Appendix 5).
This data suggests that the incidence of the disease may not have been overestimated by 
the study team, especially as the TM society data is likely to be an underestimate of the true 
incidence of TM (it only reflects individuals that actually took time to register with the 
society). However, analysis of the geographical distribution of these subjects indicated that 
more than half of these patients were more than 25 miles away from each of the recruiting 
sites (Appendix 5). This observation points towards a level of geographical disconnect 
between the potential patients and the STRIVE sites. Additionally, although local TM cases 
were often referred to, or had their treatment discussed with the investigators involved in 
the STRIVE study, it likely that some potentially eligible subjects were seen and treated 
exclusively by their local physician. The study team took steps to ensure wide dissemination 
of the study among the neurology network by inclusion of the study in the Association of 
British Neurosciences newsletter and conferences, with email to members, presentation of 
the study at the TM society annual general meeting and conference, distribution of ward 
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leaflets and admission unit posters at participating sites and provision of study flyers for use 
in district general hospitals.  
The low frequency of patient encounters was further complicated by the fact that a 
significant proportion of subjects that were considered for the trial were not eligible for 
inclusion into the study. One reason for this may be that investigators may not have wholly 
appreciated the strictness of the eligibility criteria during the feasibility assessment. Indeed 
͞stƌiĐt iŶĐlusioŶ Đƌiteƌia͟ ǁas Đited ďǇ ϴϮ% ;ϵ of ϭϭͿ of ƌespoŶdeŶts iŶ the post-trial survey as 
a key factor they believe inhibited recruitment into the study.  Notably these inclusion 
criteria were mandated by the primary endpoint of the study to be able to recruit patients 
of at least an ASIA impairment scale C to observe at least a 2-point improvement in this 
scale (see Section 11.4) This highlights the absolute necessity for further studies to establish 
a reflection of both the incidence, and equally as important, the severity of TM cases that 
are observed.   
11.3 Navigating operational barriers in setup and running of a rare 
disease trial  
Although the low frequency of patient encounters primarily led to the study under 
recruiting, other barriers played an important role in complicating the study setup and 
running, and ultimately in the recruitment of subjects into the study.  Hurdles in setting up 
the trial within the NHS sites, including contract and cost negotiation, local governance and 
a laĐk of ĐapaĐitǇ of ƌeseaƌĐh staff ;ƌeseaƌĐh Ŷuƌses aŶd/oƌ iŶǀestigatoƌs͛ ĐoŵpetiŶg 
priorities i.e. clinical and trial commitments) led to staggered opening of target sites. The 
overall impact of this is that at the time of the study closure, only 62.5% (15/24) of target 
sites were opened and recruiting. As recruitment logs were not available sites that failed to 
open (nine) the impact of the study may only be extrapolated. The impact of this is best 
understood in light of the fact that the 24 originally targeted sites were assumed to 
represent the neurology services that catered for approximately half of the UK population. 
With only 15 of these target sites open, approximately 31% of new TM/NMO cases were 
thus geographically covered.   
Lack of research capacity, described as unavailability of site research staff or co-investigator, 
or competing clinical priorities and commitments to other trials, played a significant role in 
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five (5) of the initially 24 target sites failing to open. Unsurprisingly, in the survey of 
investigators that took part in this study, 63.6% (7 of 11) of investigators found it difficult to 
run all kinds of clinical trials at the present time due to lack of time. 27.3% (3 of 11) found it 
neither difficult nor easy, whilst one investigator (9.1%) did not currently find it difficult to 
run clinical trials due to lack of time.  
The protracted contract negotiation and cost allocation highlights a wider issue of the 
differences in health service provision within different regions, in particular the 
interpretation of standard of care across different (neurology) services. For instance, whilst 
the premise of the study (which informed the funding structure) was that most of the study 
activities were within standard patient care, some of these activities, such as ASIA 
assessment, was evidently not routinely used within different neurological services. These 
differences impacted not only on the ability of target sites to be opened, but also how and 
when the site could be authorised to commence patient recruitment. Since site activation 
was predicated on at least one researcher within a site being ASIA trained, sites that did not 
routinely use this assessment tool would require a member of the research team 
(preferentially the principle investigator) to undertake the training and gain competence in 
ASIA assessment. Moreover, competency in ASIA assessment required an online training 
that may last up to 6 hours. At least one site remained unopened at the point of the study 
closure despite having all other approvals in place and having already had their site 
initiation visit. This site remained unopened as the PI was unable to complete the ASIA 
training up to the point of the study closure.  
When considering these operational barriers, it is not immediately apparent how best to 
overcome these barriers associated with research capacity. Investigators, especially 
research active ones, are likely to routinely balance clinical activities with both their existing 
and new portfolio of clinical trials; whilst R&D departments balance the low cost 
effectiveness in initiating rare disease trial with high throughput or commercial studies. 
Ultimately, fiscal remunerations for adopting very rare disease trials are likely to be required 
to facilitate running of very rare disease trials with such barriers.  
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11.4 Considerations of the design of the study 
Whilst the paucity of patient encounters and other operational barriers played a significant 
role in the study under recruiting, the contributory effect of the study design (in terms of 
eligibility criteria) to the under recruitment of the study cannot be overlooked. Analysis of 
site screening logs and feedback from investigators iŶdiĐated the eǆĐlusioŶ of ͞less seǀeƌe͟ 
(i.e. patient with ASIA impairment score of D) patients had some impact on recruitment of 
patients into the study. Approximately 48% (11 of 23) of screened patients that did not 
meet the eligibility criteria was as a ƌesult of theiƌ sǇŵptoŵs ďeiŶg ͚ŵild͛ oƌ assessed as 
ASIA impairment scale D. The study team recognised this trend whilst the study was still 
active and considered amendment of the protocol to allow inclusion of patients assessed 
ASIA D or those whose sǇŵptoŵs ǁeƌe ĐoŶsideƌed to ďe ͚ŵild͛ at the tiŵe pƌeseŶtatioŶ. 
However, the primary endpoint of the study required patients to be of at least an ASIA 
impairment scale C to observe the 2-point improvement in this scale.  
The short window for recruitment (5 days from the date of first commencement of steroid 
therapy) was the second factor identified to contributed to low recruitment. Whilst it would 
have been easy to remove this restriction, the early treatment paradigm was key to the 
study question and was deemed by study team to be important to retain.  
11.5 Achievements of STRIVE 
The barriers described individually above, and summarised in the STRIVE timeline on Figure 
3, collectively contributed to a formidable barrier that prevented the study from 
maintaining steady momentum and recruiting to target.  Nevertheless, despite the early 
termination of the study, the efforts in trying to run this trial has resulted in 2 major hidden 
rewards. Firstly, the study team has established a network of investigators comprising of 
both adult and paediatric neurologists who are ready to collaborate in future studies and 
clinical trials in TM and other neuroinflammatory conditions. Secondly, the study set-up has 
also provided key important training to the local investigator in evaluating patients with TM. 
As such, we now have 15 paediatric and adult neurology centres that is more equipped to 
manage adults and children with TM.   
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11.6 Conclusion and recommendations 
With 91% (10 of 11) of the STRIVE investigators (opinion leaders) surveyed agreeing that the 
study question is important and should be a priority, and 82% (9 of 11) of these noting that 
the outcome of the study would have changed how they treat TM patients, it is clear that 
this remains a pertinent question.  
However, a future TM intervention trial design would benefit from having a robust, up-to-
date information on incidence and distribution of severity of patients presenting with TM. 
Multi-source incidence studies in both adults and children within the intended intervention 
study population will negate need to extrapolate data.  Such a trial must also accommodate 
the evidence accrued on the spectrum of severity within patients; and thus an alternative 
outcome measure is required beyond the ASIA impairment scale. Here, prospective studies 
recruiting patients to carefully evaluate the utility of other available measures, such as the 
ASIA motor score will be required. Importantly, lessons learnt from STRIVE, are easily 
applicable to other very rare disorders.  
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Figure 3. A summary of some of the barriers encountered during the conduct of the STRIVE study
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12 Patient and public involvement  
Patient and public representatives were actively involved in the design of the research, 
management of the research and development of the participant information resources. 
Transverse myelitis society, Multiple sclerosis society and Guthy-Jackson charitable 
foundation were involved in the design of the research. Two members from the TM society 
served on the Trial Steering Committee of the study. Their involvement was crucial in both 
finalising the research protocol and patient information sheet, as well as in the overall 
direction the study took. Additionally, they provided a lay perspective on the likely public 
perceptions of the study and offered key advise on how to maximise recruitment.  
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16 Appendices 
16.1 Appendix 1: Dosing table for IVIG administration  
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16.2 Appendix 2: Clinico-radiological diagnostic algorithm 
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16.3 Appendix 3: CoŵŵoŶ side effects associated with IŶtratect ™
Intratect® can cause adverse reactions such as chills, headache, fever, vomiting, allergic 
reactions, nausea, arthralgia, low blood pressure and mild back pain, which may occur 
occasionally.  
Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in 
isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to 
previous administration.  
Cases of reversible aseptic meningitis, isolated cases of reversible haemolytic 
anaemia/haemolysis and rare cases of transient cutaneous reactions, have been observed 
with human normal immunoglobulin.  
Increase in serum creatinine level and/or acute renal failure have been observed.  
Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary 
embolism, deep vein thrombosis.  
Details of further spontaneously reported adverse reactions:  
• Cardiac disorders: Angina pectoris (very rare)  
• General disorders and administrations site conditions: Rigors (very rare)  
• Immune system disorders: Anaphylactic shock (very rare), hypersensitivity (very rare)  
• Investigations: Blood pressure decreased (very rare)  
• Musculoskeletal and connective tissue disorders: Back pain (very rare)  
• Respiratory, thoracic and mediastinal disorders: Dyspnoea NOS (very rare)  
• Vascular disorders: Shock (very rare)  
The adverse events reported above are expected, in the sense that they are possible known 
side effects of the study medication, but all reported instances of both serious and non-
serious adverse events would be reported in this study. For a more detailed list of all 
reactions, refer to Intratect Summary of Product Characteristics (SmPC):  
http://www.medicines.org.uk/emc/medicine/23175/SPC/intratect/
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16.4 Appendix 4: Futility analysis plan  
PROPOSAL FOR AN INTERIM FUTILITY ANALYSIS 
1. Introduction 
Patients suffering from transverse myelitis will be randomised equally between IV 
immunoglobulin (the experimental arm: E) and steroids (the control arm: C).  The primary 
analysis will concern response to treatment, defined as an improvement by two points on a 
paralysis assessment scale over a six-month period following treatment.  It is anticipated 
that the success rate on C will be pC = 0.5.  The trial is to have 90% power to achieve 
significance at the 0.05 level (two-sided) if the success rate on E is pE = 0.75. 
The final analysis of the study can be conducted in terms of the statistic 2 = (O – E)2/E 
which can be shown to be equal to Z2/V where  
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pC = pE = 0.5 and assuming that pC = 0.5; pC = 0.75.  The possible outcomes are then arranged 
iŶ desĐeŶdiŶg oƌdeƌ aĐĐoƌdiŶg to T, aŶd Đuŵulatiǀe pƌoďaďilities of T ďeiŶg ш eǀeƌǇ possiďle 
value from 76 to -76 are computed.  Reading the last row of the output for which 
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this case P(
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Variations to the procedure, with different sample sizes at the interim and the null can be 
evaluated, and properties under different pairs of values pC and pE can be found.  It would 
also be simple to investigate a more stringent futility criterion, requiring  to exceed a value 
such as 0.5 or 1 in order to continue.  This would make the loss of power more substantial, 
and open up the question of whether it should be compensated for by an increase in sample 
size. 
Notice that no opportunity for stopping at the interim analysis due to strong evidence of 
efficacy is allowed.  If that were allowed, then the properties of the method would need 
substantial re-evaluation and conventional analyses would no longer be conservative. 
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16.5 Appendix 5: Geographical distribution of persons diagnosed with 
TM in 2015 
 (as per Transverse Myelitis society data) in relation to STRIVE trial sites.
Where each numbered black sphere represents the number of individuals within the region on the map 
that reported (reported to TM society) to have been diagnosed with TM in 2015. Each green sphere 
represents a 25-mile radius around a STRIVE recruiting site, whilst the red spheres represent a 25-mile 
radius around STRIVE sites that were targeted for opening were the study not terminated. 
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16.6 Appendix 6: Investigator responses to the post STRIVE trial survey 
(1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree) 
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